Audit: QRS - Zinc for Health & Longevity

Audit conducted on 18/09/2026 03:00 using AI4L / Opus 5

Summary

Items	Count
Total	93
Passed	83
Failed	0
N/A	10
Pass Rate	100.00%

Total = Passed + Failed + N/A
Pass Rate = Passed / (Passed + Failed) × 100
N/A items are excluded from the pass rate calculation

1. General Rules

#	Description	Result	Comments
1.1	Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER.	🟢	All protocol doses, time-to-effect values, biomarker targets, gate items, benefit and risk items trace to ER `Therapeutic Protocol`, `Practical Considerations`, `Monitoring Protocol & Defining Success`, `Key Interactions & Contraindications`, `Expected Benefits` and `Potential Risks & Side Effects`.
1.2	Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing.	🟢	Dose-conditional hedges are carried through verbatim (“at very high doses”, “with long-term high-dose use”, “in men with low zinc status”, “Accelerated aging signal”).
1.3	The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”).	🟢	Contraindications retain “outside hepatology supervision”, “outside specialist supervision”, “without supervision”, “until repleted”, “at any dose”.
1.4	The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc.	🟢	Penicillamine/trientine correctly placed under Contraindications (ER: “Absolute contraindication”); all Monitor/Caution bullets remain Key Interactions. No modifying-factor content is surfaced as a gate.
1.5	PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact.	🟢	No PMIDs, NCT IDs, expert names or brand names appear anywhere in the QRS.
1.6	The QRS does not introduce new attributions.	🟢	No attributions present.

2. Focus, Tone & Audience

#	Description	Result	Comments
2.1	The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing.	🟢	Deflationary, evidence-first framing of the ER `Conclusion` is preserved in [at_a_glance].
2.2	The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging	🟢	Concrete doses, thresholds and biomarker targets give the reader actionable levers without exhortation.
2.3	The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor	🟢	Statements are descriptive (“Totals above 25 mg split morning and evening”), not prescriptive to a person.
2.4	The QRS avoids language that implies medical or clinical advice	🟢	No “should”, “must”, “recommend”, “advise” or “consult” in the body.
2.5	The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”	🟢	Protocol cells present parameters; Monitoring presents targets and rationale.
2.6	The QRS never addresses “the reader” directly — it presents evidence, not guidance	🟢	No second-person pronouns anywhere in the body.
2.7	The QRS is written in plain language, avoiding unnecessary medical jargon	🟢	[at_a_glance] uses “central retina damage” rather than AMD; technical marker names are confined to the Monitoring table where they are required.
2.8	Information is presented in a concise and very compact manner	🟢	Gate and tier items are noun phrases; marker rationales are single clauses.
2.9	It DOES NOT address the reader directly	🟢	Confirmed — no direct address.
2.10	The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review.	🟢	Eleven-marker monitoring panel and the 40 mg copper-displacement ceiling assume a proactive, testing-oriented reader.
2.11	The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort.	🟢	Lozenge dosing every 2–3 hours while awake and 3-monthly copper panels are retained rather than simplified away.
2.12	The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort.	🟢	Content assumes access to plasma zinc, ceruloplasmin and zinc-to-copper ratio testing.
2.13	Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience.	🟢	[at_a_glance] closes on the copper-displacement ceiling, the signal that matters specifically to a supplementing audience.
2.14	The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim.	🟢	“anti-aging” does not occur; the speculative items use “immune aging” and “Accelerated aging signal”.
2.15	The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “oral” / “administered orally” not “taken by mouth” / “given by mouth”; “injection” not “shot”; “adverse event” not “bad reaction”). This holds on EVERY surface, including the QRS lede — the stricter plain-language bar (see 2.7) does not license lay phrasing for route of administration. Direct quotes from sources are exempt.	🟢	Routes and forms are named formally (“lozenges”, “intranasal zinc”, “picolinate, citrate, gluconate or bisglycinate”); no “pill”, “shot” or “by mouth”.

3. Template Integrity

#	Description	Result	Comments
3.1	The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why”	🟢	All fourteen fixed strings match the template byte-for-byte.
3.2	All “…” from the [qrs_template] are present in the the QRS.	🟢	All 30 fixed-name spans present; the repeatable `marker_#_*` pattern is instantiated 11× and `qualitative_item_#` 6×.
3.3	Spans that are not addressed in a checklist item are left unchanged	🟢	`website="evidence_review"`, `website="audit"` and `website="full_review"` are byte-identical to the template; head, CSS block and footer diff clean against [qrs_template].

4. Formatting

#	Description	Result	Comments
4.1	When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied”	N/A	No source ER section that feeds the QRS is empty.
4.2	Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label.	🟢	“Standard maintenance dose”, “Deficiency correction” and “Cold protocol” are the ER’s bold labels verbatim.
4.3	Labels are not paraphrased, abbreviated, or invented.	🟢	Every ER-supplied label is carried verbatim; the Time-to-effect cells derive labels only because the ER bullet “Time to effect:” supplies no per-item labels.
4.4	The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels.	🟢	Zero emoji characters in the file; the ER’s “⚠️ Conflicted” markers are correctly dropped.
4.5	The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page.	🟢	Every section is condensed relative to the ER: gate items are noun phrases, tier items are semicolon lists, marker rationales are single clauses, and no ER prose is carried at length.

5. Metadata

#	Description	Result	Comments
5.1	The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content.	🟢	Lines 2–14, immediately after `<!doctype html>` on line 1.
5.2	Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML.	🟢	Opening `---` line 3, closing `---` line 13; the preceding “QRS — Metadata” line sits before the opening delimiter.
5.3	The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet.	🟢	Enclosed in an HTML comment; no duplicate of any value appears in the body.
5.4	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Only `duration: "00:02"` is quoted, correctly, because it contains a colon.
5.5	The filename of the source ER is stated as “er_filename: [er_filename]”	🟢	`er_filename: zinc_2026-0918-0002_Opus_ER.md`.
5.6	Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”	🟢	`qrs_prompt_version: 26.9.11`, matching the QRS.md version badge.
5.7	Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430)	🟢	`qrs_creation_date: 2026-0918-0242`.
5.8	The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”	🟢	`qrs_creator_ai_nickname: Opus`.
5.9	The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT)	🟢	Single word, no version.
5.10	The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”	🟢	`qrs_creator_ai_fullname: Opus 5`.
5.11	The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4)	🟢	“Opus 5” — nickname plus version, no qualifier.
5.12	The filename of the document is stated as “qrs_filename: [filename of this document]”	🟢	`qrs_filename: zinc_2026-0918-0002_Opus_QRS.html`, matching the file on disk.
5.13	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Re-verified across all nine keys; no stray whitespace or unnecessary quoting.

#	Description	Result	Comments
6.1	[page_title] is set to the [canonical_topic] of the ER `frontmatter` followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., `&` for `&`)	🟢	“Zinc for Health & Longevity - Quick Reference Sheet” (line 22); ampersand correctly encoded.
6.2	[header_topic] is set to the [canonical_topic] of the ER `frontmatter`, with HTML entities encoded as needed (e.g., `&` for `&`)	🟢	“Zinc for Health & Longevity” (line 417), matching ER `canonical_topic`.
6.3	[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]	🟢	“09/18/2026” from `qrs_creation_date: 2026-0918-0242`.
6.4	[header_subline_model] is set to [qrs_creator_ai_fullname]	🟢	“Opus 5” (line 425).
6.5	No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker.	🟢	Header contains only title and the template’s own subline; no AKA line despite the ER carrying ten alternate names.

7. At-A-Glance Section

#	Description	Result	Comments
7.1	[at_a_glance] is dense, execution-oriented summary of the ER `Conclusion` section	🟢	Compresses the four firmest findings plus the ceiling, tracking the ER `Conclusion` paragraphs 1–2.
7.2	[at_a_glance] is no longer than 60 words	🟢	55 words.
7.3	Every fact in [at_a_glance] is supported by a distinct passage in the ER.	🟢	Each clause maps to a distinct ER `Conclusion` sentence.
7.4	It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead	🟢	No acronyms; “central retina damage” replaces AMD, “blood sugar and blood fats” replaces glycemic and lipid markers.
7.5	It DOES NOT cite specific trials (names, years, sample sizes, p-values)	🟢	No trial identifiers of any kind.
7.6	It DOES NOT cite effect sizes, relative risks, or statistical results	🟢	Only the 40 mg dose threshold appears, which is a protocol ceiling rather than an effect size.

8. Contraindications

#	Description	Result	Comments
8.1	The section is derived from the ER `Key Interactions & Contraindications` section	🟢	Five items from “Populations who should avoid Zinc”, plus the penicillamine/trientine bullet flagged “Absolute contraindication”.
8.2	[stop_items] represent the Contraindications from the ER	🟢	All six ER contraindications represented; none omitted, none added.
8.3	Individual [stop_items] are formatted as <li></li>	🟢	Six discrete `<li>` elements (lines 546–557).
8.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	ER rationales “given the smell-loss signal” and “since clearance and tissue accumulation are altered” are stripped; no dash clauses remain.
8.5	Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	70 µg/dL, 18 mg/dL, 1.5 × 10⁹/L and eGFR 30 mL/min/1.73 m² all retained; only the parenthetical definition of eGFR is trimmed.
8.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER uses no ranking notation inside parentheses in this section.
8.7	The section is left empty ONLY IF the ER’s `Key Interactions & Contraindications` section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision.	🟢	The ER does identify such populations and the section is correspondingly populated.
8.8	If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

9. Key Interactions

#	Description	Result	Comments
9.1	The section is derived from the ER `Key Interactions & Contraindications` section	🟢	All eleven items map one-to-one onto ER interaction bullets.
9.2	[caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications	🟢	Twelve ER interaction bullets minus penicillamine/trientine (carried to Contraindications) = eleven items, exactly as listed.
9.3	Individual [caution_items] are formatted as <li></li>	🟢	Eleven discrete `<li>` elements (lines 565–575).
9.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	Every ER separation-interval and mechanism sentence is dropped; items are bare drug-class names. No dash clauses remain.
9.5	Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Example drug lists retained and trimmed to two exemplars each (e.g., “doxycycline, ciprofloxacin”), never dropped entirely.
9.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER uses no ranking notation inside parentheses in this section.
9.7	The section is left empty ONLY IF the ER’s `Key Interactions & Contraindications` section identifies no interaction, additive effect, or exposure that changes how the intervention is used.	🟢	The ER identifies twelve such interactions and the section is correspondingly populated.
9.8	If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

10. Protocol

#	Description	Result	Comments
10.1	The section is derived from the ER `Protocol` section	🟢	All three cells derive from ER `Therapeutic Protocol` bullets, with the split-dosing detail from the same section.
10.2	The three sets of [action] items cover the three most important actionable implementation aspects from the ER `Protocol` section	🟢	Maintenance dosing, deficiency correction and the cold protocol are the three broadly applicable regimens; the eye protocol is indication-specific.
10.3	If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER supplies more than three actionable aspects; all three sets are used.
10.4	All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER `Protocol` section.	🟢	All nine spans carry ER-derived content; no placeholders remain.

11. Time to Effect

#	Description	Result	Comments
11.1	The three sets of [time] items cover the three most important time-to-effect aspects from the ER	🟢	Cold duration, blood sugar/lipids and eye-disease protection — the three horizons named in the ER “Time to effect” bullet.
11.2	The sets are picked and ordered by the magnitude of the related benefit	🟢	Order matches the ER `Expected Benefits` High-tier sequence: common cold, glycemic control and lipids, then macular degeneration.
11.3	If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER names four time-to-effect horizons; all three sets are used.
11.4	All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER.	🟢	“24–48 hours”, “8–12 weeks” and “Years” with ER-derived subtexts, including the 4-week plasma normalization detail.
11.5	If the ER does not provide any information on time to effect, the section is removed completely from the `Protocol Panel`	N/A	The ER provides time-to-effect information; the section is correctly retained.

12. Benefits

#	Description	Result	Comments
12.1	The section is derived from the ER `Expected Benefits` section	🟢	All twelve items correspond to ER benefit subheadings across the four tiers.
12.2	Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]	🟢	All four spans present and populated (lines 529–536).
12.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Each item is a short noun phrase; no magnitudes, confidence intervals or trial counts carried over.
12.4	Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses appear in any benefits item.
12.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four tiers carry items in the ER, so none needs hiding.

13. Risks

#	Description	Result	Comments
13.1	The section is derived from the ER `Potential Risks & Side Effects` section	🟢	All nine ER risk subheadings are represented across the four tiers.
13.2	Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]	🟢	All four spans present and populated (lines 587–592).
13.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	The three “at very high doses” Low-tier risks are factored into one shared clause; no relative risks or case counts carried over.
13.4	Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses appear in any risks item.
13.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four tiers carry items in the ER, so none needs hiding.

14. Monitoring

#	Description	Result	Comments
14.1	The section is derived from the ER `Monitoring` section	🟢	Table and cadence derive from ER `Monitoring Protocol & Defining Success`.
14.2	All measurable/quantifiable biomarkers from the `Monitoring` section are listed	🟢	All eleven ER table rows present in ER order, with targets matching (plasma zinc, serum copper, ceruloplasmin, zinc-to-copper ratio, complete blood count, ferritin, alkaline phosphatase, hs-CRP, HbA1c, HDL cholesterol, PSA).
14.3	[monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER `Monitoring` section. It is not left with placeholder text or empty.	🟢	Baseline, 3 months, 12 months, then annually, with the 3-monthly escalation above 40 mg daily — matching the ER narrative paragraph.

15. Qualitative Assessment

#	Description	Result	Comments
15.1	The section is derived from the ER `Monitoring` section	🟢	Derived from the ER’s “Qualitative markers worth tracking alongside the laboratory values” list.
15.2	All subjective/qualitative biomarkers from the `Monitoring` section are listed	🟢	All six ER qualitative markers present in ER order, including the copper-related neuropathy warning.

Issues 18/09/2026 03:00

Pass rate 100.00%. No issues found.

Issues 18/09/2026 02:51

12.3 / 12.4 — Conflicted qualifier in Benefits: benefits_medium (line 530) preserves the parenthetical evidence-strength qualifier “(conflicted)” on “Fewer infections in older adults”, which sections 12.3/12.4 require to be stripped because the tier label already encodes evidence strength.
13.3 / 13.4 — Conflicted qualifiers in Risks: risks_low (line 589) preserves two parenthetical “(conflicted)” qualifiers — after “lower HDL cholesterol” and after “advanced prostate cancer risk with long-term high-dose use” — which sections 13.3/13.4 require to be stripped.

Fixes 18/09/2026 02:51

12.3 / 12.4 — Conflicted qualifier in Benefits: Stripped the parenthetical “(conflicted)” from benefits_medium, changing “Fewer infections in older adults (conflicted)” to “Fewer infections in older adults”.
13.3 / 13.4 — Conflicted qualifiers in Risks: Stripped both parenthetical “(conflicted)” markers from risks_low, after “lower HDL cholesterol” and after “advanced prostate cancer risk with long-term high-dose use”.

Issues 18/09/2026 02:47

4.5 — QRS overruns one A4 page: Body content runs to roughly two A4 pages: the Key Interactions gate wraps to ~20 lines (lines 587–602), the 11-row Monitoring table carries full-sentence “Why” text and multi-line targets (lines 650–806), the cadence paragraph is ~370 characters (lines 811–816), and the six qualitative items are full sentences (lines 824–859).

Fixes 18/09/2026 02:47

4.5 — Monitoring “Why” column condensed: Rewrote all eleven marker_#_why cells from full sentences to short phrases (e.g. “The single most important safety marker; falls before symptoms appear” to “The most important safety marker; falls before symptoms appear”), cutting most rows from two or three wrapped lines to one.
4.5 — Multi-line monitoring targets shortened: Trimmed marker_5_target, marker_6_target, marker_10_target and marker_11_target (e.g. “50–150 ng/mL (men), 40–100 ng/mL (women)” to “50–150 ng/mL (men), 40–100 (women)”), keeping every threshold value.
4.5 — Monitoring cadence tightened: Reduced the cadence paragraph from ~370 to ~260 characters while retaining the baseline, 3-month, 12-month, annual and >40 mg 3-monthly escalation schedule.
4.5 — Key Interactions gate compressed: Trimmed example drug lists to representative members across the eleven items (e.g. “Integrase inhibitors (dolutegravir, raltegravir, bictegravir)” to “(dolutegravir, bictegravir)”; “Blood-sugar-lowering supplements … and glucose-lowering drugs (metformin, sulfonylureas)” to “Glucose-lowering drugs and supplements (metformin, berberine)”), taking the gate from ~20 to ~13 wrapped lines with every drug class still represented.
4.5 — Contraindications gate compressed: Shortened all six items without dropping a threshold (e.g. “Documented copper deficiency (serum copper below 70 µg/dL …) until copper is repleted” to “Copper deficiency (copper below 70 µg/dL …) until repleted”).
4.5 — Qualitative items shortened: Cut the six items to their key observation (e.g. “Energy levels and exercise recovery, which decline with both zinc deficiency and copper depletion” to “Energy levels and exercise recovery”), taking the card to one line per item.
4.5 — Benefits and Risks lists tightened: Compressed the High benefits list and grouped the three very-high-dose risks in the Low tier, keeping all twelve benefits and ten risks and both “(conflicted)” markers.
4.5 — Protocol sub-cells trimmed: Shortened action_1_sub and action_2_sub (e.g. “step down to a maintenance dose” to “step down to maintenance”) to keep the three protocol cells at equal height.

Total visible body text reduced from roughly 6,600 to roughly 5,360 characters. All 73 data-qrs-var spans, all eleven biomarkers, all six qualitative markers, all six contraindications and all eleven key interactions remain present.